You are here

P&T News

October 20

Morphine/naltrexone combo expected to reduce oral abuse when crushed
Flexible custom mask covers hollow eye socket at lower cost
Disease ignored by public, neglected by doctors, experts say

October 17

Progressive scarring of lungs leaves patients short of breath
British research focused on the role of enzymes in bacteria
Top-line results released in NIH-funded comparison of effectiveness
Studies will prepare vaccine candidate for clinical trials

October 16

New data support efficacy of chimeric antigen receptor therapy
Longer period might be needed to prevent virus spread, expert says
Medications and nonpharmacologic recommendations graded

October 15

Replaceable device allows urination without catheterization
Novel antipsychotic and improved rescue therapy take center stage by 2023
Additional exposures were expected, agency says

October 14

Drug’s effect on weight change, sexual function similar to that of placebo
Approval decision expected in April 2015
Soliris takes the prize at nearly $537,000 per year
Modified sulfonylurea stimulates insulin release

October 13

Drug’s effect on weight change, sexual function similar to that of placebo

October 13

Certain patients with genotype-1 infections need just 8 weeks of treatment
Living-cell bioformulation fails to provide significant improvement
Health care worker is first to develop disease in U.S.
Harvard discovery could help prevent clotting and infections

October 12

Living-cell bioformulation fails to provide significant improvement
Health care worker is first to develop disease in U.S.
Harvard discovery could help prevent clotting and infections

October 10

Array of genetic defects thwart targeted treatments
Author identifies financial constraints on antibiotic research

October 8

Oral nucleotide analog demonstrates antiviral activity
Symptoms and severity of the illness are frightening, expert admits

October 7

Potential treatment covers all five viral species
Switching of currently treated patients is likely to be limited
Dopamine antagonist reduces post-op nausea & vomiting

Pages

P&T TV

2 Lenalidomide Regimens in the FIRST Trial (MM-020/IFM 07 01) in Newly Diagnosed Multiple Myeloma Patients: Initial Phase 3 Results

Thierry Facon, MD, of Hopital Claude Huriez, CHRU Lille in France, concludes that in newly diagnosed multiple myeloma patients who are ineligible for stem cell transplantation, the FIRST trial establishes continuous lenalidomide therapy as a new standard of care.

American Society of Hematology

Meetings

Nashville, TN
November 3 to November 4
Brussels, Belgium
November 12 to November 14

Free App

MediMedia App IconManaged Care, and P&T are available for free on multiple mobile platforms and devices. For Apple and iOS devices, visit the Apple Store and download the free digital application for Managed Care and P&T. Search for "Managed Care," "Pharmacy and Therapeutics," or "MediMedia."

Users of Android, Blackberry, Nook, and Kindle can view the mobile version on their respective devices by visiting these Web sites: Managed Care and P&T.